Showing results (2121-2130 of 2,317) with videos related to

Sort By:
Pageof 232
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Microbiology Spectrum|January 5, 2023
Subcellular Distribution of BALF2 and the Role of Rab1 in the Formation of Epstein-Barr Virus Cytoplasmic Assembly Compartment and Virion ReleaseTsung-Yu Chao, Yi-Ying Cheng, Zi-Yun Wang, et al.
Frontiers in Oncology|December 15, 2022
Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemiaFang-Min Zhong, Fang-Yi Yao, Jing Liu, et al.
The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2014
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trialCalin Cainap, Shukui Qin, Wen-Tsung Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Translational Lung Cancer Research|September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment optionsJiu-Wei Cui, Qing Zhou, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
The Lancet. Oncology|May 19, 2015
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialJin Li, Shukui Qin, Ruihua Xu, et al.
Science Advances|November 23, 2022
Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer modelWai Nam Liu, Wing Yan So, Sarah L Harden, et al.
Pageof 232